# EDGAR Filing Document

**Accession Number:** 0000899923
**File Stem:** 0000899923-25-000089
**Filing Date:** 2025-8
**Character Count:** 12752
**Document Hash:** b86382927b0cb773d7a3d2136feedbea
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000899923-25-000089.hdr.sgml**: 20250818

**ACCESSION NUMBER**: 0000899923-25-000089

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20250815

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250818

**DATE AS OF CHANGE**: 20250818

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MYRIAD GENETICS INC
- **CENTRAL INDEX KEY:** 0000899923
- **STANDARD INDUSTRIAL CLASSIFICATION:** IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 870494517
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-26642
- **FILM NUMBER:** 251226349

**BUSINESS ADDRESS:**
- **STREET 1:** 322 NORTH 2200 WEST
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84116
- **BUSINESS PHONE:** 801-584-3600

**MAIL ADDRESS:**
- **STREET 1:** 322 NORTH 2200 WEST
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84116

?xml version='1.0' encoding='ASCII'? mygn-20250815

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): August 15, 2025**

**MYRIAD GENETICS, INC.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **0-26642** | **87-0494517** |
| **(State or other jurisdiction of<br>incorporation)** | **(Commission<br>File Number)** | **(IRS Employer<br>Identification No.)** |

---

**322 North 2200 West**

**Salt Lake City, Utah 84116**

**(Address of principal executive offices) (Zip Code)**

**Registrant's telephone number, including area code: (801) 584-3600**

**Not applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.01 par value | MYGN | Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

*Departure of Scott J. Leffler as Chief Financial Officer*

On August 18, 2025, Myriad Genetics, Inc. (the "Company") announced that, effective August 15, 2025, Scott J. Leffler no longer serves as Chief Financial Officer of the Company. Mr. Leffler is expected to remain as a non-executive employee of the Company for an interim period to assist in the transition of his responsibilities.

*Appointment of Ben R. Wheeler as Chief Financial Officer*

On August 14, 2025, the Company's Board of Directors (the "Board") appointed Ben R. Wheeler, currently serving as the Company's Senior Vice President, Chief Financial Officer, Operations, as the Company's Chief Financial Officer and principal financial officer, effective August 16, 2025. Mr. Wheeler's appointment as Chief Financial Officer was announced by the Company via press release on August 18, 2025.

Mr. Wheeler, 42, has served in various roles of increasing responsibility at the Company over the past thirteen years, including most recently as Senior Vice President, Chief Financial Officer, Operations, since June 2022, and Senior Vice President, Finance and Treasury, since July 2020. Mr. Wheeler has also served at the Company as Senior Vice President, Accounting, from June 2018 to July 2020, Vice President, Corporate Controller, from December 2014 to June 2018, and in other controllership positions from December 2011 to December 2014. Before joining the Company, Mr. Wheeler served as an auditor for Ernst & Young. Mr. Wheeler holds both master's and bachelor's degrees in accounting from Brigham Young University and is a Certified Public Accountant.

There are no arrangements or understandings between Mr. Wheeler and any other person pursuant to which he was appointed as an officer of the Company. Mr. Wheeler does not have any family relationship with any director or other executive officer of the Company and is not party to any related party transactions required to be reported pursuant to Item 404(a) of Regulation S-K.

In connection with his appointment, the Company entered into an employment agreement with Mr. Wheeler, dated August 14, 2025 (the "Employment Agreement"), setting forth the terms of Mr. Wheeler's employment, including his compensation and the commencement of his employment as Chief Financial Officer on August 16, 2025 (the "Commencement Date"). Pursuant to the Employment Agreement, Mr. Wheeler will be paid an annual base salary of $490,000. Mr. Wheeler will be eligible to receive an annual target cash bonus equal to 75% of his annual base salary upon achievement of goals to be established by the Compensation and Human Capital Committee of the Board (the "CHCC") or the Chief Executive Officer each fiscal year and will be eligible to participate in the Company's annual long-term incentive compensation program. Mr. Wheeler will also be eligible to participate in the standard health, welfare and retirement benefit plans that are applicable to similarly situated executives of the Company. The Employment Agreement also provides for an initial one-time grant of restricted stock units (the "Initial Grant") to Mr. Wheeler in connection with his promotion. The Initial Grant was granted on the Commencement Date and consisted of (i) 60,000 restricted stock units, subject to standard time-based vesting, and (ii) 60,000 restricted stock units, subject to vesting upon satisfaction of certain performance metrics and standard time-based vesting, as determined by the CHCC in its sole discretion, and subject to Mr. Wheeler's continued service to the Company through the applicable vesting dates.

The Company and Mr. Wheeler also entered into the Company's standard Employee Invention Assignment, Confidentiality, and Restrictive Covenants Agreement, Severance and Change of Control Agreement and Indemnification Agreement.

The foregoing description of the Employment Agreement does not purport to be complete and is qualified in its entirety by the full text of such agreement, a copy of which will be filed with the Company's Quarterly Report on Form 10-Q for the fiscal quarter ending September 30, 2025.

 **ITEM 7.01 Regulation FD Disclosure.**

A copy of the press release announcing Mr. Leffler's departure and Mr. Wheeler's appointment as Chief Financial Officer and principal financial officer on the Commencement Date is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

------

**ITEM 9.01&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.**

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Description** |
| 99.1 | <u>[Press Release dated](ex-991myriadgeneticspressr.htm)[Aug](ex-991myriadgeneticspressr.htm)[ust 18, 2](ex-991myriadgeneticspressr.htm)[025](ex-991myriadgeneticspressr.htm)[.](ex-991myriadgeneticspressr.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **MYRIAD GENETICS, INC.** | **MYRIAD GENETICS, INC.** |
| Date: August 18, 2025 | By: | /s/ Benjamin Richard Wheeler |
|  |  | Benjamin Richard Wheeler |
|  |  | Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![imagea.jpg](imagea.jpg)

**Myriad Genetics Appoints Ben Wheeler Chief Financial Officer**

**SALT LAKE CITY,** August 18, 2025 – <u>Myriad Genetics, Inc</u>. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Ben Wheeler has been promoted to Chief Financial Officer, effective August 16, 2025.

Ben has been with Myriad for more than 13 years, joining the Company in December 2011 as assistant controller and advancing through leadership roles including vice president, corporate controller; senior vice president, accounting; and since 2022, chief financial officer, operations.

Scott Leffler, who has served as Chief Financial Officer since January 2024, will transition to a consulting role serving the CEO and the Board of Directors through September 2, 2025.

"We want to thank Scott for his contributions to Myriad," said Sam Raha, President and CEO of Myriad Genetics. "We are happy to have Ben as our next CFO. His extensive knowledge of our business, strong financial expertise, and proven leadership will be instrumental in enabling the execution of our profitable growth strategy going forward."

"I'm excited for this opportunity to lead the finance team and play a pivotal role in advancing Myriad's mission and long-term growth strategy," said Mr. Wheeler. "I look forward to partnering with Sam and the rest of the executive team to positively impact an increasing number of patient lives and to generate lasting value for our shareholders."

The company is reaffirming its financial guidance for the full-year 2025, as announced during its second quarter 2025 earnings call on August 5, 2025.

**About Myriad Genetics**

Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit <u>www.myriad.com</u>.

------

**Safe Harbor Statement** <br>This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including that the company is reaffirming its financial guidance for the full-year 2025, as announced during its second quarter 2025 earnings call, and that Mr. Wheeler's extensive knowledge of the company's business, strong financial expertise, and proven leadership will be instrumental in enabling the execution of the company's profitable growth strategy going forward. These "forward-looking statements" are management's expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company's filings with the U.S. Securities and Exchange Commission, including the company's Annual Report on Form 10-K filed on February 28, 2025, as well as any updates to those risk factors filed from time to time in the company's Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.

**Investor Contact** 

Matt Scalo

(801) 584-3532

<u>IR@myriad.com</u> 

**Media Contact** 

Katie Schraml

(224) 875-4493

<u>PR@myriad.com</u> 

###

<br>